AMARIN CORP PLC\UK Cash and Cash Equivalents
AMARIN CORP PLC\UK (AMRN) had Cash and Cash Equivalents of $143.56 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-29
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $143.56M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $131.06M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $134.66M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $122.80M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $143.56M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $131.06M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $134.66M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $122.80M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $147.88M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $119.52M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $121.04M 10-K · filed 2026-03-02 |
| 2024-09-30 | $156.94M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $215.92M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $213.94M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $199.25M 10-K · filed 2025-03-12 |
| 2023-09-30 | $270.81M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $233.00M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $191.41M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $217.67M 10-K · filed 2024-02-29 |
| 2022-09-30 | $240.50M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $228.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $219.15M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $219.45M 10-K · filed 2023-03-01 |
| 2021-09-30 | $222.88M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $327.02M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $290.99M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $186.96M 10-K · filed 2022-03-01 |
| 2020-09-30 | $207.21M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $214.01M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $329.05M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $644.59M 10-K · filed 2021-02-25 |
| 2019-09-30 | $673.21M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $221.77M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $211.09M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $249.23M 10-K · filed 2020-02-25 |
| 2018-09-30 | $81.89M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $102.26M 10-Q · filed 2018-08-01 |
| 2018-03-31 | $129.05M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $73.64M 10-K · filed 2019-02-27 |
| 2017-09-30 | $79.09M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $85.46M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $96.08M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $98.25M 10-K · filed 2018-02-27 |
| 2016-09-30 | $117.56M 10-Q · filed 2017-11-01 |
| 2016-06-30 | $72.49M 10-Q · filed 2017-08-02 |
| 2016-03-31 | $81.36M 10-Q · filed 2017-05-03 |
| 2015-12-31 | $106.96M 10-K · filed 2018-02-27 |
| 2015-09-30 | $118.98M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $136.05M 10-Q · filed 2016-08-04 |
| 2015-03-31 | $161.19M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $119.54M 10-K · filed 2018-02-27 |
| 2014-09-30 | $135.44M 10-Q · filed 2015-11-04 |
| 2014-06-30 | $150.53M 10-Q · filed 2015-08-06 |
| 2014-03-31 | $164.28M 10-Q · filed 2015-05-08 |
| 2013-12-31 | $191.51M 10-K · filed 2017-03-01 |
| 2013-09-30 | $225.88M 10-Q · filed 2014-11-06 |
| 2013-06-30 | $149.43M 10-Q · filed 2014-08-07 |
| 2013-03-31 | $201.78M 10-Q · filed 2014-05-09 |
| 2012-12-31 | $260.24M 10-K · filed 2016-02-25 |
| 2012-09-30 | $215.11M 10-Q · filed 2013-11-07 |
| 2012-06-30 | $250.25M 10-Q · filed 2013-08-08 |
| 2012-03-31 | $245.82M 10-Q · filed 2013-05-09 |
| 2011-12-31 | $116.60M 10-K · filed 2015-03-03 |
| 2011-09-30 | $125.86M 10-Q · filed 2012-11-08 |
| 2011-06-30 | $131.45M 10-Q · filed 2012-08-08 |
| 2011-03-31 | $129.48M 10-Q · filed 2012-05-08 |
| 2010-12-31 | $31.44M 10-K · filed 2014-02-27 |
| 2010-09-30 | $31.48M 10-Q · filed 2011-11-08 |
| 2010-06-30 | $37.74M 10-Q · filed 2011-08-09 |
| 2009-12-31 | $52.26M 10-K · filed 2013-02-28 |
| 2008-12-31 | $14.24M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |